In this interview, Nicolette G. Payne, MD, discusses a recent study pointing to an increase in burnout among pediatric urologists since the 2016 American Urological Association Census, emphasizing ...

Panelists discuss the expanding clinical development of cretostimogene across multiple NMIBC populations and treatment strategies, highlighting ongoing trials exploring its use as monotherapy and in ...

Panelists discuss the final BOND-3 trial results, highlighting intravesical cretostimogene’s strong efficacy, durable responses, and excellent safety profile in BCG-unresponsive carcinoma in situ (CIS ...

Surgical therapy for ED is rare, with only 1.1% of patients undergoing procedures in community-based urology practices in the US. Racial and ethnic disparities exist in the time to surgical therapy, ...

The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.

In a recent interview, Kevin T. McVary, MD, FACS, discussed the expanded FDA label for the Rezūm System, which now includes prostate volumes up to 150 cm 3, a significant increase from the previous ...

In a groundbreaking cross-border collaboration, Cleveland Clinic urologists recently completed the world's first remotely performed robot-assisted high-intensity focused ultrasound (HIFU) focal ...

Amy E. Krambeck, MD, discusses how to define success and how to determine the optimal timing for adding on a new partner. On the former, Krambeck noted that it’s important to take into account number ...

Key Takeaways Lutetium (177Lu) rhPSMA-10.1 showed higher radiation doses in tumors than in normal organs, indicating a favorable therapeutic index in mCRPC patients. The phase 1 trial demonstrated a ...

The test utilizes chromosomal instability signatures to predict resistance to taxane-based chemotherapy in metastatic prostate cancer.

Oral sulopenem was approved by the FDA in October 2024 based in part on results from the REASSURE trial. 3 Specifically, the antibiotic is indicated for the treatment of uUTI caused by the designated ...

Key Takeaways Detalimogene voraplasmid received RMAT designation, expediting its development for high-risk BCG-unresponsive NMIBC with CIS. The investigational therapy is a non-viral gene-based ...